Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.200
0.00 (0.00%)
At close: Dec 5, 2025, 4:00 PM EST
2.220
+0.020 (0.91%)
After-hours: Dec 5, 2025, 7:55 PM EST
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Iovance Biotherapeutics stock have an average target of 10.36, with a low estimate of 2.00 and a high estimate of 20. The average target predicts an increase of 370.91% from the current stock price of 2.20.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 4 | 4 | 4 | 5 | 5 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $4 → $9 | Buy | Maintains | $4 → $9 | +309.09% | Nov 24, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 → $17 | Strong Buy | Maintains | $20 → $17 | +672.73% | Nov 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $9 | Strong Buy | Maintains | $20 → $9 | +309.09% | Oct 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +809.09% | Aug 19, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $14 | Buy | Maintains | $18 → $14 | +536.36% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
264.06M
from 164.07M
Increased by 60.94%
Revenue Next Year
424.75M
from 264.06M
Increased by 60.85%
EPS This Year
-1.07
from -1.28
EPS Next Year
-0.60
from -1.07
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 283.5M | 567.4M | ||||
| Avg | 264.1M | 424.8M | ||||
| Low | 246.0M | 333.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 72.8% | 114.9% | ||||
| Avg | 60.9% | 60.9% | ||||
| Low | 49.9% | 26.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.87 | -0.40 | ||||
| Avg | -1.07 | -0.60 | ||||
| Low | -1.13 | -1.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.